PLASMA KINETICS AND BILIARY-EXCRETION OF COLCHICINE IN PATIENTS WITH CHRONIC LIVER-DISEASE AFTER ORAL-ADMINISTRATION OF A SINGLE-DOSE AND AFTER LONG-TERM TREATMENT

被引:26
作者
RUDI, J
RAEDSCH, R
GERTEIS, C
SCHLENKER, T
PLACHKY, J
WALTERSACK, I
SABOURAUD, A
SCHERRMANN, JM
KOMMERELL, B
机构
[1] UNIV HEIDELBERG, DEPT MED, DIV CLIN PHARMACOL, W-6900 HEIDELBERG, GERMANY
[2] UNIV PARIS, HOP FERNAND WIDAL, INSERM, U26, F-75252 PARIS, FRANCE
关键词
BILIARY EXCRETION; COLCHICINE; LIVER DISEASES; PLASMA CONCENTRATIONS; PRIMARY BILIARY CIRRHOSIS;
D O I
10.3109/00365529409094847
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease were evaluated after oral administration of a single dose and after long-term treatment. A single oral dose of 1 mg colchicine led to a mean peak concentration of 3.60 +/- 1.04 ng/ml at a peak time of 2.16 +/- 0.34 h and a mean area under the plasma concentration time curve, extrapolated from time 0 to infinity, of 24.90 +/- 8.47 ng.h/ml. Comparable values were obtained after repeated administration. Distribution half-life was 2.83 +/- 0.74h, and terminal plasma elimination half-life was 9.81 +/- 2.08 h; the mean apparent volume of distribution and the mean apparent plasma clearance were 1448 +/- 4061 and 175.3 +/- 47.61/h, respectively. Colchicine concentrations in bile (2025 +/- 1368 ng/ml) were clearly higher than in plasma. Long-term treatment with colchicine (1 mg/day) in patients with various stages of primary biliary cirrhosis (PBC) was associated with colchicine concentrations varying from <0.15 to 2.0 ng/ml, with a slight tendency to higher concentrations in PBC stages III-IV than I-II, Although about 20% of colchicine is excreted in bile within 24 h, accumulation of colchicine may appear only in patients with advanced liver disease and cholestasis.
引用
收藏
页码:346 / 351
页数:6
相关论文
共 36 条
[1]   PHARMACOKINETICS - BIOAVAILABILITY OF COLCHICINE IN HEALTHY MALE-VOLUNTEERS [J].
ACHTERT, G ;
SCHERRMANN, JM ;
CHRISTEN, MO .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1989, 14 (04) :317-322
[2]   EVALUATION OF COLCHICINE THERAPY IN PRIMARY BILIARY-CIRRHOSIS [J].
BODENHEIMER, H ;
SCHAFFNER, F ;
PEZZULLO, J .
GASTROENTEROLOGY, 1988, 95 (01) :124-129
[3]  
BOURDON R, 1980, TOXICOL LETT, P116
[4]  
BRUCE AM, 1942, J CLIN INVEST, V21, P646
[5]   COLCHICINE THERAPY FOR FAMILIAL MEDITERRANEAN FEVER - DOUBLE-BLIND TRIAL [J].
DINARELLO, CA ;
WOLFF, SM ;
GOLDFINGER, SE ;
DALE, DC ;
ALLING, DW .
NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (18) :934-937
[6]   PATHWAYS OF EXCRETION OF COLCHICINE IN GOLDEN HAMSTER [J].
FLEISCHMANN, W ;
PRICE, HG ;
FLEISCHMANN, SK .
PHARMACOLOGIST, 1968, 1 (01) :48-+
[7]   COLCHICINE KINETICS IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER [J].
HALKIN, H ;
DANY, S ;
GREENWALD, M ;
SHNAPS, Y ;
TIROSH, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (01) :82-87
[8]   EFFECTS OF COLCHICINE ON COLLAGENASE IN CULTURES OF RHEUMATOID SYNOVIUM [J].
HARRIS, ED ;
KRANE, SM .
ARTHRITIS AND RHEUMATISM, 1971, 14 (06) :669-+
[9]  
HEINZEL G, 1993, PHARMACOKINETIC PHAR
[10]  
HUNTER AL, 1975, J PHARMACOL EXP THER, V192, P605